Troponin-I is not falsely elevated in asymptomatic dialysis patients

Hussein, Magdi; Mooij, J. M. V.; Malki, Najla Al; Demerdash, Tarek M; Mandourah, Abdullah Y

doi:10.4103/1319-2442.106240

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Management strategies include surgery and antitubercular therapy. Hemodialysis and other symptomatic management of CKD were carried out 22 . Recent reports indicate that a combination of surgery and chemotherapy shows better results compared to chemotherapy alone 19,23–25 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A rare extrapulmonary manifestation of tuberculosis in a chronic kidney disease patient

Sivanandam,

Jhoond,

Sujanyal

et al. 2023

Clinical Case Reports

View full text Add to dashboard Cite

Key Clinical MessageChronic kidney disease (CKD) and tuberculoma are two distinct medical conditions. Nonetheless, they can be related in very rare cases. The purpose of this case report is to consider screening tests such as IGRA (interferon gamma release assay) and TST (tuberculin skin test), for tuberculosis in CKD patients with a risk of infection, thereby increasing the awareness of tuberculoma in CKD and ensuring early treatment which would eventually decrease the morbidity and mortality rates in such patients.AbstractChronic kidney disease (CKD) associated with tuberculoma represents one of the rarest conditions occurring worldwide. Among tuberculous patients, only 1% show central nervous system involvement. We present a case of a 45‐year‐old male with CKD who presented with a seizure and was diagnosed to have tuberculoma.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Hemodialysis and other symptomatic management of CKD were carried out. 22 Recent reports indicate that a combination of surgery and chemotherapy shows better results compared to chemotherapy alone. 19,[23][24][25] In our case, a similar treatment strategy was followed.…”

Section: F I G U R E 3 Intraoperative Image Showing a Mass Lesionmentioning

confidence: 99%

A rare extrapulmonary manifestation of tuberculosis in a chronic kidney disease patient

Sivanandam,

Jhoond,

Sujanyal

et al. 2023

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…[23] Allen et al [9] suggested prudent application of troponin testing in SVT patients due to low cardiovascular risk. However, given the higher prevalence of cardiovascular disease in ESKD patients than the general population, [24] most of the patients with ESKD (91.9%) were tested for cTnI level when presenting SVT in the ED of our institution, resulting in a markedly prolonged length of hospital stay. In the current study, more previous medical histories were present in the cTnI-positive group compared with the cTnI-negative group.…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of cardiac troponin in dialysis patients with paroxysmal supraventricular tachycardia

et al. 2022

View full text Add to dashboard Cite

A rise in cardiac troponin I (cTnI) is common in supraventricular tachycardia (SVT). While troponin elevation in SVT is thought to be a predictor of future adverse events in patients with prior coronary artery disease, the prognostic significance of cTnI in endstage kidney disease (ESKD) patients with SVT are not known. We aimed to examine the prognostic significance of cTnI in ESKD patients presenting with SVT in the emergency department. This was a retrospective, multiple-center observational study utilizing regularly collected electronic medical records. We screened electronic medical records of all dialysis patients presenting to the emergency departments in 5 hospitals over 12 years with SVT. These patients were divided into whether cTnI was tested, and were further stratified into the cTnI-positive and cTnI-negative groups. The primary outcome of the study was the 3-year risk of major adverse cardiovascular events (MACE). Sixty-two patients were qualified for inclusion. Fifty-seven patients (91.9%) were tested for cTnI, and 5 patients were not. Patients with the cTnI test were older (P = .03) and had a longer length of hospital stay (P < .001). Forty-seven patients (82.5%) had a positive result, and 10 (17.5%) had a negative result. A history of hypertension (P = .013) and decreased left ventricular ejection fraction (P = .048) were the independent predictors of cTnI elevation. After a mean follow-up period of 20.6 ± 14.7 months, there were no differences in 3-year MACE between patients with or without elevated cTnI levels in Kaplan-Meier analysis (P = .34). A history of coronary artery disease was the only independent predictor of 3-year MACE (P = .017). Through the subgroup analysis, a history of coronary artery disease (HR 2.73; CI 1.01-7.41; P = .049) remained an independent risk factor for 3-year MACE in patients with elevated cTnI levels. A large proportion (82.5%) of troponin elevation was observed in ESKD patients with SVT, but it had a poor correlation with MACE.

show abstract

Silver-enhanced colloidal gold dip strip immunoassay integrated with smartphone-based colorimetry for sensitive detection of cardiac marker troponin I

Poosinuntakul

Chanmee

Porntadavity

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Cardiac troponin I (cTnI) is a specific cardiac biomarker for diagnosis of acute myocardial infarction (AMI). A sensitive and simple point-of-care test (POCT) is still required for early detection of AMI. To address this need, we developed a dip strip assay based on sandwich immunoassay coupled with a silver enhancement system. Pre-incubation and silver enhancement were introduced to the dip strip to increase sensitivity. Due to the catalytic reaction of the silver enhancement solution, the red color of AuNPs changed to dark brown as silver ions precipitated and enlarged the AuNPs. The obtained results were easily seen by the naked eye. For quantitative analysis, the color intensity of the results was analyzed using a smartphone with RGB color picker application. The effects of operating parameters (volume of AuNP-Ab conjugate, volume of sample, incubation time, and analysis time) were investigated and optimized. Under optimal conditions, the limit of detection (LOD) by the naked eye was 0.5 ng/mL. The LOD with silver enhancement was 50-fold lower than without. For quantitative analysis using the smartphone, linearity of detection was observed through the range of 0.5–50 ng/mL (R2 = 0.9952) and the LOD was 0.12 ng/mL. The developed method was successfully applied to detection of cTnI in serum samples, achieving analytical recoveries and %RSD in the ranges of 96.10–119.17% and 2.91–5.13%, respectively. Additionally, this developed assay was not cross reactive with the potentially interfering serum proteins. These results showed the great potential of this dip strip assay as an alternative POCT for detection of serum cTnI.

show abstract

Troponin-I is not falsely elevated in asymptomatic dialysis patients

Cited by 4 publications

References 0 publications

A rare extrapulmonary manifestation of tuberculosis in a chronic kidney disease patient

A rare extrapulmonary manifestation of tuberculosis in a chronic kidney disease patient

Prognostic value of cardiac troponin in dialysis patients with paroxysmal supraventricular tachycardia

Silver-enhanced colloidal gold dip strip immunoassay integrated with smartphone-based colorimetry for sensitive detection of cardiac marker troponin I

Contact Info

Product

Resources

About